BPC-157

Each lot of BPC-157 is characterized by analytical methods to confirm identity and purity:

• HPLC — purity verified to ≥99% (area %), with the exact value reported on the lot-specific COA.
• Mass spectrometry (MS) — used to confirm molecular identity against the expected monoisotopic/average mass (reported on the COA).
• Reference identifiers — CAS No. 137525-51-0; pentadecapeptide, average molecular weight approximately 1419.5 Da, as characterized on the lot COA.
• Certificate of Analysis — a per-lot COA documenting HPLC purity and MS identity accompanies each batch.

These laboratory tests are analytical characterizations of identity and purity only. They are not assessments of safety, efficacy, or fitness for any human or veterinary application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by Zynix Biolab.

BPC-157 is a synthetic pentadecapeptide (15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponding to a partial sequence reported in the literature as derived from a protein found in human gastric juice. In the published scientific literature it has been characterized as a cytoprotective compound and has been the subject of extensive preclinical investigation.

The compound has been studied predominantly in in vitro and animal (preclinical) models. Reports in the literature have examined signaling associated with angiogenesis, including the VEGFR2 pathway and nitric-oxide (eNOS) signaling. A 2025 systematic review of the published record identified several hundred articles spanning 1993–2024 across PubMed, Cochrane, and Embase, the large majority of which describe non-clinical work.

Regarding human-stage research conducted by third parties, a Phase I safety and pharmacokinetic study of an orally administered formulation was registered on ClinicalTrials.gov as NCT02637284 and listed as completed in 2015. As reported in independent coverage and regulatory statements, BPC-157 has not been approved by the FDA or any other regulatory authority, and published human clinical data remain very limited.

This study-phase information refers to research conducted and published by independent third parties. It does not represent testing or approval by Zynix Biolab. For research use only, not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published scientific literature, BPC-157 has been used as a research compound in non-clinical laboratory and animal-model studies. Lines of investigation reported by third parties include:

• Cytoprotection and tissue-repair models — examined in in vitro and animal systems characterizing wound-healing and gastrointestinal-protection endpoints.
• Angiogenesis-associated signaling — studied in relation to the VEGFR2 pathway and nitric-oxide (eNOS) signaling.
• Fibroblast and endothelial cell behavior — investigated in cell-based assays as part of repair-pathway characterization.

These applications describe laboratory research with the compound only and do not constitute any form of human use.

The research applications above are provided for scientific context only. This product is not for human use, diagnostic use, or therapeutic use.

General laboratory handling guidance for the lyophilized research material:

• Storage — store lyophilized powder at -20°C, protected from light and moisture; avoid repeated freeze-thaw cycles of any prepared solution.
• Reconstitution — for laboratory preparation, the lyophilized peptide may be reconstituted with bacteriostatic water or another suitable laboratory solvent; aliquot and store reconstituted solutions cold per standard peptide-handling practice.
• PPE — handle with appropriate personal protective equipment (gloves, lab coat, eye protection) under standard laboratory safety procedures.

This handling, storage, and reconstitution guidance describes standard laboratory practice for research materials and is not a dosing or administration instruction. For research use only — not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

• Sikiric P, et al. Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectomized rats. PubMed PMID: 9149058.
• Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. PubMed PMID: 22300085.
• Sikiric P, et al. Fistulas healing. Stable gastric pentadecapeptide BPC 157 therapy. PubMed PMID: 32329684.
• ClinicalTrials.gov registry entry — Safety and pharmacokinetics study of an orally administered BPC-157 formulation (Phase I). NCT02637284.

These references describe independent third-party research and are provided for scientific context only and are not claims by Zynix Biolab.